Picture loading failed.

Pre-Made Ulocuplumab biosimilar, Whole mAb, Anti-CXCR4 Antibody: Anti-FB22/HM89/LAP3/LCR1/NPYR/WHIM/CD184/LAP-3/LESTR/NPY3R/NPYRL/WHIMS/HSY3RR/NPYY3R/WHIMS1/D2S201E therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ulocuplumab (INN; development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-600-1mg 1mg 3090
GMP-Bios-ab-600-10mg 10mg Inquiry
GMP-Bios-ab-600-100mg 100mg Inquiry
GMP-Bios-ab-600-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Ulocuplumab biosimilar, Whole mAb, Anti-CXCR4 Antibody: Anti-FB22/HM89/LAP3/LCR1/NPYR/WHIM/CD184/LAP-3/LESTR/NPY3R/NPYRL/WHIMS/HSY3RR/NPYY3R/WHIMS1/D2S201E therapeutic antibody
INN Name Ulocuplumab
TargetCXCR4
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesBristol-Myers Squibb;Medarex;University of Bari
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours
Conditions DiscontinuedB-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma
Development Techna